CYNO Cynosure - Class A (MM)

- SmartSense(TM) for Smartlipo(TM): The World's First Intelligent Delivery System for Laser Lipolysis WESTFORD, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the introduction of three aesthetic products for fast-growing applications including laser lipolysis, the removal of pigmented lesions and ablative skin resurfacing. Cynosure will showcase its new products, SmartSense(TM) for Smartlipo(TM), Accolade(TM) and Affirm Er, at the American Academy of Dermatology (AAD) 2008 Annual Meeting, which kicks off tomorrow in San Antonio, Texas. "Cynosure's strategic vision is centered on the continuous improvement of aesthetic procedures through technology innovations that benefit patients and practitioners," said Michael Davin, Cynosure's president and chief executive officer. "Each of the products we are launching today fulfills that mission. Accolade, the sixth flagship product we have introduced in the past four years, creates exciting new revenue opportunities for us, particularly in markets throughout Asia, while SmartSense and Affirm Er enhance the benefits and performance of our two most recently introduced workstations." SmartSense for Smartlipo -- Delivering Precise Energy Control to LaserBodySculpting Recently FDA cleared, SmartSense is a proprietary intelligent handpiece delivery system for Smartlipo, Cynosure's ground-breaking, minimally invasive system that liquefies and removes localized deposits of fat and results in tissue tightening through tissue coagulation. SmartSense features an advanced microchip, the Accelerometer, which is inserted into the intelligent handpiece, to ensure the precise level of energy is delivered based on the area of treatment and predetermined settings in conjunction with the motion of the handpiece. "SmartSense provides our customers with an unparalleled degree of safety, precision and control that is not available with any other laser lipolysis technology," Davin said. "Based on the setting you choose and the motion of the handpiece, SmartSense provides aesthetic surgeons with the precise laser power to perform laser lipolysis. To provide the maximum level of patient safety, if handpiece motion ceases SmartSense will stop the laser from firing, but remains ready and resumes firing once the handpiece is set in motion again." "SmartSense is an excellent addition to the Smartlipo workstation because it allows me to tailor the level of energy to the demands of the specific clinical indication," said Barry Di Bernardo, M.D., medical director of New Jersey Plastic Surgery. "This not only helps to achieve a more consistent clinical outcome, but also adds an extra layer of safety and piece of mind for my patients. I look forward to incorporating the SmartSense into my laser lipolysis practice." Accolade -- State-of-the-Art Technology to Remove Pigmented Lesions Accolade is a high powered 755 nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser's high repetition rates allow for rapid treatment. The initial target markets for Accolade will include Japan, Korea and China, where dermal lesions such as Nevus of Ota and Nevus of Ito are common. "Given the market potential for this technology, particularly in the Asia Pacific region, we are excited about the prospects for Accolade," Davin said. "As a flagship product, Accolade is expected to generate a minimum of $10 million in revenue in its first full year on the market." Affirm Er -- Ablative Skin Resurfacing with Minimal Downtime Cynosure's new Affirm Er is a 2940 nm wavelength, Erbium: YAG laser for ablative skin resurfacing applications, such as the treatment of deep lines and wrinkles. The Affirm Er handpiece is designed as a complementary fourth wavelength for the Affirm Anti-Aging workstation, Cynosure's award-winning platform for anti-aging applications such as skin rejuvenation, wrinkles, skin discoloration and tissue tightening. "With the introduction of Affirm Er, we are responding to growing demand for an ablative technology that best addresses the treatment of deep lines and wrinkles," Davin said. "Since its introduction a year ago, our innovative Affirm workstation has been enthusiastically received by the marketplace, both in the U.S. and overseas. By adding the Erbium wavelength, we are further increasing the versatility, flexibility and cost-effectiveness of Affirm for our customers." Bruce E. Katz, M.D., director of the Juva Skin & Laser Center, said, "For our patients, the Affirm system has been extremely effective in the treatment of wrinkles and scars, while tightening the underlying tissue. Some patients want a more rapid therapy for deep lines and wrinkles. The addition of this ablative component expands Affirm's ability to address the anti-aging marketplace." According to the Millennium Research Group, the skin rejuvenation market is expected to grow annually by 18 percent, resulting in a $239 million industry by 2010, with approximately 4.4 million procedures performed per year by 2010. About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Safe Harbor Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward- looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617.542.5300 DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon Merrill Associates, Inc., +1-617-542-5300, Web site: http://www.aad.org/professionals/MeetingsEvents/66AM.htm http://www.cynosure.com/

Copyright